Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Tesla stock declines with shares of the electric-vehicle maker down for the past seven weeks, Redfin agrees to be acquired by ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...

European shares were down sharply on Monday, giving up early gains as worries over a possible US recession mounted in the wake of the February jobs report published the day before.

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

A sell-off across US markets has continued as investor sentiment soured amid growing fears that the world’s largest economy ...

Novo Nordisk (NVO, Financial) shares fell 8% on Monday morning following disappointing Phase 3 trial results for its weight ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

FOA has just signed an agreement with DI for private sector pedagogical assistants and educational assistants. The deal includes a salary boost of more than 3,000 DKK per month by 2027, along with ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...